Award candidates and winners to be presented on October 26, 2023, at the Prix Galien USA Forum in NYC.
The Galien Foundation announced the 2023 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," and "Incubators, Accelerators and Equity." And, in partnership with Business France, nominees have also been announced for "Best Startup." Winners will be announced during the Prix Galien USA Forum on October 26, 2023, at the Alexandria Center for Life Science in New York City. Category winners will be announced during the Prix Galien USA Awards Ceremony at the American Museum of Natural History in New York City.
"The Prix Galien Awards Committee is delighted to celebrate this remarkable group of candidates and selecting this year's winners will be no easy feat," said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Prix Galien Medical Technology, Startup, Digital Health and Incubators, Accelerators and Equity Committee Chairman. "This great list of nominees reflects the undeniable courage, dedication, and passion behind each researcher continually working to deliver answers to patients around the world. We applaud their efforts and look forward to celebrating our shared goal of improving the human condition".
Specifically, in the Digital Health Solution category, nominees from the clinical trials sector include: Empatica, Medable, Science 37, uMotif and Viz.AI. The full list of nominees is below.
"I'm honored to be returning as an Awards juror as we commend the unwavering commitment of each winner and award nominee in their perseverance of the advancement of global science, healthcare, and wellness," said Alex Gorsky, Former CEO and Executive Chairman, Johnson & Johnson, member of the Prix Galien Startup, Digital Health and Incubators, Accelerators and Equity Committee. "The outstanding quality of the submissions is a testament to the promising future of the life sciences industries."
Best Digital Health Solution (Nominees)
Reference: The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup". NEW YORK, July 27, 2023 /PRNewswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.